GLP-1 Costs: Major Barrier to Treatment for 68% of Users
Rising costs are a significant barrier to access for GLP-1 medications, a class of drugs increasingly used for both type 2 diabetes and weight management, according to a new survey released . Nearly seven in ten Americans who have used these medications report that the cost influenced their decision to start or continue treatment.
GLP-1s and Their Growing Popularity
GLP-1 (glucagon-like peptide-1) medications have gained prominence in recent years due to their clinical effectiveness and expanding range of applications. Originally developed to manage type 2 diabetes, these drugs – including popular brand names like Ozempic, Wegovy, Mounjaro, and Zepbound – have also been approved for chronic weight management. This expansion, coupled with direct-to-consumer advertising, has led to a surge in demand.
These medications work by mimicking the effects of the naturally occurring GLP-1 hormone, which helps regulate blood sugar levels and appetite. They can lead to significant improvements in glycemic control for individuals with type 2 diabetes and substantial weight loss for those struggling with obesity. However, the benefits come at a cost, and that cost is proving to be a major obstacle for many patients.
The Financial Burden
The Navitus Health Solutions Pulse Survey, which questioned 2,000 Americans who have taken GLP-1 medications in the last two years, revealed the extent of the financial strain. GLP-1 medications offer meaningful health benefits, but this survey highlights trends and concerns related to medication cost and long-term accessibility to these drugs,
said Sharon Faust, Chief Pharmacy Officer at Navitus Health Solutions.
The survey data showed that 24% of respondents reported paying more than $250 per prescription fill, with nearly 8% facing costs of $500 or more. This substantial out-of-pocket expense creates difficult tradeoffs
for patients, according to Faust, and raises concerns about the long-term sustainability of treatment.
Implications for Patients and the Healthcare System
The high cost of GLP-1s isn’t just a personal financial issue; it has broader implications for the U.S. Healthcare system. As demand for these medications continues to increase – a trend anticipated by Navitus Health Solutions – ensuring access for appropriate patients while maintaining financial stability becomes increasingly critical. Faust emphasized the need to make sure that the appropriate patients can get the medications they need while ensuring financial stability within the U.S. Health-care system.
The survey findings underscore the importance of addressing affordability challenges to prevent patients from discontinuing treatment. Discontinuation is a concern not only because it can reverse the health benefits achieved while on the medication, but also because it can lead to increased healthcare costs in the long run if underlying conditions worsen.
Beyond Cost: Considerations for Long-Term Use
The rising cost of GLP-1s is occurring alongside growing awareness of the potential consequences of stopping these medications. The survey results suggest that affordability concerns may contribute to discontinuation, raising questions about the long-term effectiveness of these treatments and the potential for a cycle of starting and stopping medication due to financial constraints.
The medications are indicated for managing Type 2 diabetes and chronic weight management, among other conditions. The survey highlights the complex interplay between clinical benefits, financial accessibility, and the need for sustainable healthcare solutions. The increasing demand for GLP-1s, driven by proven effectiveness and expanded indications, necessitates a proactive approach to ensure that these potentially life-changing medications remain within reach for those who need them.
The findings from Navitus Health Solutions add to a growing body of evidence demonstrating the significant financial burden faced by patients accessing GLP-1 medications. , 68% of GLP-1 users cited rising costs as a major treatment barrier, according to reports from the American Journal of Managed Care.